Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CSNK2A2 | P19784 | 4/20 | 0.34 |
| ▸ | CSNK2B | P67870 | 4/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 10/20 | 0.33 |
| ▸ | PRNP | P04156 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.31 |
| ▸ | PLK1 | P53350 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4801611 | 0.81 | CYP1A2 (0.45) | CYP1A2CYP2C19ALDH1A1MKNK1 | |
| SCHEMBL5067504 | 0.71 | ALDH1A1 (0.40) | ALDH1A1LMNACSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL5065447 | 0.69 | ALDH1A1 (0.50) | CYP1A2ALDH1A1LMNACSNK2A2CSNK2B | |
| SCHEMBL4800416 | 0.67 | ALDH1A1 (0.41) | CYP1A2ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL14050407 | 0.65 | MKNK1 (0.36) | ALDH1A1LMNACSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL14032004 | 0.65 | ALDH1A1 (0.33) | ALDH1A1LMNA | |
| SCHEMBL16024218 | 0.64 | MKNK1 (0.45) | SMN1; SMN2MKNK1 | |
| SCHEMBL5064157 | 0.63 | ALDH1A1 (0.41) | CYP1A2ALDH1A1LMNANOTUMMKNK1 | |
| SCHEMBL20505765 | 0.63 | MKNK2 (0.56) | ALDH1A1SMN1; SMN2HTTMKNK1 | |
| SCHEMBL24401465 | 0.63 | NOTUM (0.43) | ALDH1A1LMNANOTUMSMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269238-A1 | Thiazolopyrimidine Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-30 | — | — | US | disclosed |
| US-20080269238-A1 | Thiazolopyrimidine Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-30 | — | — | US | disclosed |
| US-20080269238-A1 | Thiazolopyrimidine Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-30 | — | — | US | disclosed |
| EP-1731523-A1 | THIAZOLOPYRIMIDINE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2006-12-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269238-A1 | Thiazolopyrimidine Derivative | FGFR3, FGFR1, ERBB3 | CYP1A2 805/4885CYP2C19 426/4885ALDH1A1 1911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.